KNSA · Kiniksa Pharmaceuticals International, plc

The thesis

Kiniksa Pharmaceuticals International's re-rating rests on ARCALYST, its recurrent-pericarditis drug. The third-quarter report on 27 October 2026 settles whether full-year guidance rises again from $980–995 million. The shares closed at $80.79 on 22 October 2026, 2.9% below the $83.17 52-week high and 27.2% higher over three months, so much of the July good news is already in the price.

On 28 July 2026 the company raised 2026 ARCALYST net-product-revenue guidance from $930–945 million. Second-quarter ARCALYST revenue was $243.6 million, about 55% above the year-earlier quarter, against a $225.5 million analyst estimate cited by Benzinga. The narrative is maturing: the story is well known, targets were reset on 29 July 2026, and interest has narrowed to one test, the next guidance range. The company confirmed the report date and an 8:30 a.m. Eastern call on 22 October 2026, and the same day it named Ross Moat President and Chief Operating Officer.

Bullish and bearish views on Kiniksa Pharmaceuticals International, plc

The bull case on Kiniksa Pharmaceuticals International, plc (KNSA), in brief: Guidance moved to $980–995 million against a $940.1 million analyst estimate. The bear case: Another raise is not yet reported.

Bull case

• Guidance moved to $980–995 million against a $940.1 million analyst estimate.
• Management sees patients still untreated. At the end of the second quarter, Kiniksa estimated that roughly 21% of 14,000 multiple-recurrence pericarditis patients were actively on ARCALYST. More than 5,000 prescribers had written prescriptions since launch (Kiniksa Q2 release, 28 July 2026).
• Analyst targets sit above the price. After the second-quarter report, JPMorgan set a $107 target, Citigroup $100, Wedbush $99 and Canaccord Genuity $98, all reported by MarketBeat on 29 July 2026.
• Cash covers the pipeline work. Kiniksa held $525.9 million in cash, equivalents and short-term investments with no debt at 30 June 2026, while its KPL-387 pivotal trial was enrolling.
• Expectations for the quarter are higher again. MarketBeat's consensus on 20 October 2026 was $0.3722 per share and $260.21 million in revenue for the third quarter, up from the $243.6 million second-quarter ARCALYST figure.

Bear case

• Another raise is not yet reported. The $980–995 million range issued on 28 July 2026 is the latest guidance. A reiterated or lower range on 27 October 2026 would remove the main support for the re-rating.
• The shares have already moved. The adjusted close was $80.79 on 22 October 2026, up 27.2% over three months, with a 14-day relative strength index of 64.6. The 52-week high is now $83.17, above the $80.92 high cited in the prior note, so the shares have already traded higher and pulled back.
• An earnings date sits days away. Quarterly results on 27 October 2026 concentrate the risk into one session, and the July report moved the shares more than 20% in a day, per Benzinga on 28 July 2026.
• Some targets trail the price. Goldman Sachs set a $75 target on 23 July 2026 and Wells Fargo a $74 target on 13 July 2026, both before the second-quarter report, per Benzinga. Both sit below the latest close; either firm may have revised since.
• Insider paperwork exists. Kiniksa's SEC filings page listed a Form 144 (a notice of a planned share sale) and several Form 4 insider-transaction filings dated 3 September 2026. Sales by insiders into strength are a crowding signal if they recur.

Price setup

The adjusted daily close was $80.79 on 22 October 2026, 2.9% below the $83.17 52-week high. The 14-day relative strength index of 64.6 sits below the level usually read as stretched, and the three-month gain is 27.2%.

The weekly close below $70 that would end the case is about 13% under the latest close. It sits under the range the shares have held since the July report.

Catalysts, next 30 days

• 27 October 2026: third-quarter 2026 results, with a live webcast at 8:30 a.m. Eastern. The report decides whether the $980–995 million ARCALYST range rises, and whether revenue approaches the $260.21 million MarketBeat consensus.
• After 27 October 2026: analysts typically revise targets within a day or two of a report; JPMorgan's $107 and Citigroup's $100 are the reference points set in July.

What would change the view

The case breaks if the 27 October 2026 report leaves the $980–995 million range unchanged or lowers it, or if ARCALYST revenue falls short of the roughly $260 million consensus. A weekly close below $70 would also end it. A deferral of the 2028 or 2029 KPL-387 commercialization expectation would weaken the pipeline leg of the case. A raise that lifts the shares through the $83.17 high would show the market still extends credit for growth.

What it trades with

No theme cluster currently carries Kiniksa, and its shares trade mainly on ARCALYST sales and guidance. Its revenue comes from one marketed product for recurrent pericarditis, so the large-cap biotech index is a loose guide at best. Earnings-day moves in smaller commercial-stage drugmakers, such as the more than 20% move on 28 July 2026, have come from company-specific guidance rather than sector flows.